Dexcom Inc
NASDAQ:DXCM
Dexcom Inc
Capital Expenditures
Dexcom Inc
Capital Expenditures Peer Comparison
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Dexcom Inc
NASDAQ:DXCM
|
Capital Expenditures
-$218.8m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-36%
|
|
Becton Dickinson and Co
NYSE:BDX
|
Capital Expenditures
-$782m
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-3%
|
|
Boston Scientific Corp
NYSE:BSX
|
Capital Expenditures
-$779m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-10%
|
|
Stryker Corp
NYSE:SYK
|
Capital Expenditures
-$612m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-11%
|
|
Abbott Laboratories
NYSE:ABT
|
Capital Expenditures
-$2.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-7%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Capital Expenditures
-$1.1B
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-26%
|
See Also
What is Dexcom Inc's Capital Expenditures?
Capital Expenditures
-218.8m
USD
Based on the financial report for Mar 31, 2024, Dexcom Inc's Capital Expenditures amounts to -218.8m USD.
What is Dexcom Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-36%
Over the last year, the Capital Expenditures growth was 35%. The average annual Capital Expenditures growth rates for Dexcom Inc have been 6% over the past three years , -19% over the past five years , and -36% over the past ten years .